These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 31505325)

  • 1. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.
    Kim MH; Seong JB; Huh JW; Bae YC; Lee HS; Lee DS
    Redox Biol; 2020 Jan; 28():101315. PubMed ID: 31505325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y; Choi SI; Hong E; Kim GH
    J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in obese mouse models induced by a high-fat diet.
    Kim MH; Park SJ; Kim JH; Seong JB; Kim KM; Woo HA; Lee DS
    Free Radic Biol Med; 2018 Aug; 123():27-38. PubMed ID: 29777756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
    Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling.
    Song K; Zhang Y; Ga Q; Bai Z; Ge RL
    Life Sci; 2020 Jul; 252():117633. PubMed ID: 32289432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NF
    Ding X; Jian T; Li J; Lv H; Tong B; Li J; Meng X; Ren B; Chen J
    Oxid Med Cell Longev; 2020; 2020():9734560. PubMed ID: 33204402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
    Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
    J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice.
    Vida M; Gavito AL; Pavón FJ; Bautista D; Serrano A; Suarez J; Arrabal S; Decara J; Romero-Cuevas M; Rodríguez de Fonseca F; Baixeras E
    Dis Model Mech; 2015 Jul; 8(7):721-31. PubMed ID: 26035386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
    BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice.
    Liu S; Yuan J; Yue W; Bi Y; Shen X; Gao J; Xu X; Lu Z
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3257-3267. PubMed ID: 30006154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
    Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
    World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Bae S; Lee YH; Lee J; Park J; Jun W
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558538
    [No Abstract]   [Full Text] [Related]  

  • 20. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
    Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
    Cells; 2019 May; 8(5):. PubMed ID: 31083505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.